drugset
drugset / Trial / NCT01349569

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

NCT01349569 ↗

Phase 2 Completed 19 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This research is being done to find out if the investigators can improve outcomes for multiple myeloma patients by giving a myeloma vaccine to patients who are already on lenalidomide (Revlimid) and in a near complete remission.

Timeline

Start
2012-01
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Myeloma Vaccine Vaccine — Other
Background Lenalidomide Other / unclassified 5 mg Oral
Background Lenalidomide Other / unclassified 10 mg Oral
Background Lenalidomide Other / unclassified 15 mg Oral
Background Lenalidomide Other / unclassified 25 mg Oral
Background Prevnar 13 Vaccine 0.5 ml Intramuscular

Indications

plasma cell myeloma